Abstract
N-methyl-D-aspartate (NMDA) receptors play essential roles in the normal physiology of neurons, and these receptors are also largely responsible for glutamate-induced excitotoxicity. Since treatments of glutamate-induced excitotoxicity by NMDA receptor inhibitors often result in adverse side effects, alternative treatment approaches have been actively sought in recent years. One potential approach is to target proteins and enzymes down stream of the NMDA receptor signaling pathways. Extensive studies in recent years have demonstrated that PDZ domains of PSD-95 play critical roles in scaffolding the NMDA receptor/neuronal nitric oxide synthase pathway. Therefore, PSD-95 PDZ domains become attractive targets for treatment of glutamate-induced overproduction of nitric oxide. The strategy is to develop small compounds that can effectively block protein-protein interactions mediated by the PDZ domains of PSD-95. Biochemical and structural studies of PDZ/target interactions have indicated that developing small molecules to compete with PDZ targets is a feasible approach. We provide an example demonstrating the discovery and further development of small molecules capable of disrupting PSD-95/NMDA receptor and/or PSD-95/neuronal nitric oxide synthase complexes.
Keywords: Excitotoxicity, stroke, NMDA receptor, PSD-95, PDZ, neuronal nitric oxide synthase, protein-protein interaction
Current Topics in Medicinal Chemistry
Title: Targeting PDZ Domain Proteins for Treating NMDA Receptor-Mediated Excitotoxicity
Volume: 6 Issue: 7
Author(s): Wenyu Wen, Wenning Wang and Mingjie Zhang
Affiliation:
Keywords: Excitotoxicity, stroke, NMDA receptor, PSD-95, PDZ, neuronal nitric oxide synthase, protein-protein interaction
Abstract: N-methyl-D-aspartate (NMDA) receptors play essential roles in the normal physiology of neurons, and these receptors are also largely responsible for glutamate-induced excitotoxicity. Since treatments of glutamate-induced excitotoxicity by NMDA receptor inhibitors often result in adverse side effects, alternative treatment approaches have been actively sought in recent years. One potential approach is to target proteins and enzymes down stream of the NMDA receptor signaling pathways. Extensive studies in recent years have demonstrated that PDZ domains of PSD-95 play critical roles in scaffolding the NMDA receptor/neuronal nitric oxide synthase pathway. Therefore, PSD-95 PDZ domains become attractive targets for treatment of glutamate-induced overproduction of nitric oxide. The strategy is to develop small compounds that can effectively block protein-protein interactions mediated by the PDZ domains of PSD-95. Biochemical and structural studies of PDZ/target interactions have indicated that developing small molecules to compete with PDZ targets is a feasible approach. We provide an example demonstrating the discovery and further development of small molecules capable of disrupting PSD-95/NMDA receptor and/or PSD-95/neuronal nitric oxide synthase complexes.
Export Options
About this article
Cite this article as:
Wen Wenyu, Wang Wenning and Zhang Mingjie, Targeting PDZ Domain Proteins for Treating NMDA Receptor-Mediated Excitotoxicity, Current Topics in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/156802606776894474
DOI https://dx.doi.org/10.2174/156802606776894474 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lovastatin Reduces Apoptosis and Downregulates the CD40 Expression Induced by TNF-α in Cerebral Vascular Endothelial Cells
Current Neurovascular Research Stem Cell Therapies for Intracerebral Hemorrhages
Current Drug Delivery Patent Selections
Recent Patents on Cardiovascular Drug Discovery Identification of Functional Variants Associated with Obesity in Pakistani Kindred
Current Chinese Science Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design Early Urinary Markers for Diabetic and Other Kidney Diseases
Current Drug Targets Physicochemical, Functional and Antioxidant Properties of Diplazium esculentum Leaf Protein Concentrate
Current Traditional Medicine Patient, System and Clinician Level Interventions to Address Disparities in Diabetes Care
Current Diabetes Reviews Radiolabelled Peptides and Monoclonal Antibodies for Therapy Decision Making in Inflammatory Diseases
Current Pharmaceutical Design Electrochemical Behavior of Triflusal, Aspirin and their Metabolites at Glassy Carbon and Boron Doped Diamond Electrodes
Combinatorial Chemistry & High Throughput Screening AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Cross-talk Between Exogenous Statins and Endogenous High-Density Lipoprotein in Anti-Inflammatory and Anti-Atherogenic Actions
Endocrine, Metabolic & Immune Disorders - Drug Targets Acknowledgements to Reviewers
Cardiovascular & Hematological Disorders-Drug Targets Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Role of Ox-LDL and LOX-1 in Atherogenesis
Current Medicinal Chemistry Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Green Tea Polyphenols as an Anti-Oxidant and Anti-Inflammatory Agent for Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Antioxidants as a Potential Therapy Against Age-Related Neurodegenerative Diseases: Amyloid Beta Toxicity and Alzheimers Disease
Current Pharmaceutical Design